Sage Therapeutics' SAGE-718 Gets FDA ODD; Bullish View On TeraWulf
- October 18th, 2023
- 589 views
Shares of Sage Therapeutics, Inc. (Nasdaq: SAGE), a leading biopharmaceutical company specializing in neurological and neuropsychiatric disorders, surged over 5% in pre-market trading after the company said that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) to SAGE-718, a potential treatment for Huntington’s disease (HD).
HD, a rare and progressive neurodegenerative condition, impacts an estimated 40,000 U.S. adults annually, with severe cognitive effects.
$SAGE was trading at $21.05 in pre-market, up $1.41 (7.18%).
In other news, Stifel has initiated coverage on TeraWulf Inc. (Nasdaq: WULF), an infrastructure-focused bitcoin mining company, with a Buy rating and set a price target of $3.
Based on Tuesday's closing price of $1.24, the assigned price target implies a potential upside of $1.76 or approximately 141.94% for $WULF, according to the investment banking firm's view.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
Key Earnings Ahead for Netflix, Fastenal, and U.S. Bancorp
January 18th, 2026Louisville Thunder Appoints Veteran Coach Mike Reed to Lead Program
January 15th, 2026FDA Approves First Treatment for Children With Menkes Disease
January 13th, 2026January 13th, 2026Wall Street Eyes Bank of America, Wells Fargo, Citi Ahead of Earnings
January 11th, 2026
Member Login